High materiality7/10
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results
Why it may matterVerify against the original reporting
Upside driven by valuation upside versus current price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James maintains Market Outperform on KURA following Q2 results; target $24; current price $11.89. Positive valuation upside implied.
- Raymond James reiterates Market Outperform; target $24 vs $11.89.
Key facts
- 01
Target: $24
- 02
Posted price: $11.89
- 03
Analyst firm: Raymond James
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.